The amino acid creatine is essential for muscle and brain health, and people commonly use creatine supplements to improve exercise performance and increase muscle mass. Results from a clinical trial published in Food Science & Nutrition indicate that dietary creatine may also benefit individuals experiencing post-COVID-19 fatigue syndrome (also known as long COVID).
The amino acid creatine is essential for muscle and brain health, and people commonly use creatine supplements to improve exercise performance and increase muscle mass. Results from a clinical trial published inindicate that dietary creatine may also benefit individuals experiencing post-COVID-19 fatigue syndrome .
In the trial, 12 people with post-COVID-19 fatigue syndrome were randomized to take a placebo or 4 grams of creatine monohydrate per day for six months. Creatine intake caused a significant increase in creatine levels in leg muscles and across the brain at both three-month and six-month follow-ups. Creatine supplementation also led to a significant reduction in general fatigue after three months of intake, and it significantly improved scores for several post-COVID-19 fatigue syndrome–related symptoms—including loss of taste, breathing difficulties, body aches, headaches, and difficulties concentrating—at the 6-month follow up.
"Endorsing creatine might be of great importance in tackling this prevalent condition, but additional studies are warranted to confirm our findings in various post-COVID-19 cohorts," said corresponding author Sergej M. Ostojic, MD, Ph.D., of the University of Novi Sad, in Serbia.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Research team leads adaptive, efficient multi-arm phase 2 clinical trial for glioblastomaAn innovative phase 2 clinical trial led by Dana-Farber Cancer Institute, in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma, has reported initial results in the Journal of Clinical Oncology. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that benefit patients.
Read more »
Li-Fraumeni Syndrome: Woman with rare condition given clinical trial hopeElla Hines, 24, has Li-Fraumeni Syndrome, which increases her chances of getting cancer by 90%.
Read more »
Clinical trial recommends methotrexate for children with severe atopic dermatitisA study led by King's College London compared the safety and efficacy of ciclosporin with methotrexate in children and young people with severe atopic dermatitis, a debilitating skin condition. They also examined whether the severity of the disease changed or returned after treatment ended.
Read more »
Pre-clinical research indicates mRNA vaccine shows promise for reducing cases of Lyme diseaseAn experimental mRNA vaccine provides protection in preclinical animal models against infection from Borrelia burgdorferi, the bacteria that causes Lyme disease, according to new research from the Perelman School of Medicine at the University of Pennsylvania. Results from these preclinical animal models suggest that the vaccine prevents the development of Lyme disease and may represent a powerful tool in reducing the number of Lyme disease cases.
Read more »
Early convalescent plasma use—helpful in avoiding severe COVID—also may lower long COVID riskFindings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing post-COVID conditions—commonly known as long COVID—if they receive early treatment with plasma from convalescent (recovered) COVID patients that contain antibodies against SARS-CoV-2, the virus that causes COVID-19.
Read more »
Early treatment with convalescent plasma may reduce risk of long COVIDFindings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing post-COVID conditions -; commonly known as long COVID -; if they receive early treatment with plasma from convalescent (recovered) COVID patients that contain antibodies against SARS-CoV-2, the virus that causes COVID-19.
Read more »